RA ℞: Anti-GM-CSF - Arthritis Rheumatism

High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab

Despite recent advances in treatment of rheumatoid…

rheumnow.com

Agent that Targets GM-CSF Shows Promise in RA

Novel monoclonal antibody was rapidly effective in mild-to-moderate disease

medpagetoday.com

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Namilumab (AMG203) is an immunoglobulin G1 monoclonal antibody that binds with high affinity to the GM-CSF ligand. This was a phase 1b, randomized, double-blind study (PRIORA) to assess namilumab in active, mild-to-moderate rheumatoid arthritis (RA). The primary outcome was the safety and tolerabili…

arthritis-research.biomedcentral.com

High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab

Agent that Targets GM-CSF Shows Promise in RA

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

FARRER CLINIC

NOVENA CLINIC

High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab

Agent that Targets GM-CSF Shows Promise in RA

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

<img decoding="async" src="https://static-content.springer.com/image/art%3A10.1186%2Fs13075-017-1267-3/MediaObjects/13075_2017_1267_Fig1_HTML.gif" alt="">

FARRER CLINIC

NOVENA CLINIC